Support for association of HSPG2 with tardive dyskinesia in Caucasian populations

Pharmacogenomics Journal

Volumn 12, Issue 6, 2012, Pages 513-520

  Greenbaum, L ^a   Alkelai, A ^a   Zozulinsky, P ^a   Kohn, Y ^a   Lerer, B ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

antipsychotics; HSPG2; schizophrenia; tardive dyskinesia

Indexed keywords

ADULT; ALLELE; ARTICLE; CAUCASIAN; CONTROLLED STUDY; DISEASE MARKER; DISEASE PREDISPOSITION; ETHNIC GROUP; FEMALE; GENE; GENE FUNCTION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC RISK; HSPG2 GENE; HUMAN; JEWISH ISRAELI; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REPLICATION STUDY; RISK ASSESSMENT; RISK FACTOR; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; TARDIVE DYSKINESIA;

ADULT; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HEPARAN SULFATE PROTEOGLYCANS; HUMANS; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; MOVEMENT DISORDERS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84870056486     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2011.32     Document Type: Article

References (59)

1. Blanchet PJ. Antipsychotic drug-induced movement disorders. Can J Neurol Sci 2003; 30: S101-S107.
2. Haddad PM, Dursun SM. Neurological complications of psychiatric drugs: clinical features and management. Hum Psychopharmacol 2008; 23(Suppl): 15-26.
3. Glazer WM, Morgenstern H, Doucette JT. Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications. J Clin Psychiatry 1993; 54: 133-139.
4. de Leon J. The effect of atypical versus typical antipsychotics on tardive dyskinesia: a Naturalistic Study. Eur Arch Psychiatry Clin Neurosci 2007; 257: 169-172.
5. Remington G. Tardive dyskinesia: eliminated, forgotten, or overshadowed? Curr Opin Psychiatry 2007; 20: 131-137.
6. Correll CU, Schenk EM. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry 2008; 21: 151-156.
7. Yassa R, Jeste DV. Gender differences in tardive dyskinesia: a critical review of the literature. Schizophrenia Bull 1992; 18: 701-715.
8. Kane JM. Tardive dyskinesia: epidemiological and clinical presentation. In: Bloom FE, Kupfer DJ (eds). Psychopharmacology: The 4th Generation of Progress. Raven Press: New York, 1995.
9. Tenback DE, van Harten PN, van Os J. Non-therapeutic risk factors for onset of tardive dyskinesia in schizophrenia: a meta-analysis. Mov Disord 2009; 24: 2309-2315.
10. Lerer B, Segman RH. Pharmacogenetics of antipsychotic therapy: pivotal research issues and the prospects for clinical implementation. Dialogues Clin Neurosci 2006; 8: 85-94.
11. Muller DJ, Schulze TG, Knapp M, Held T, Krauss H, Weber T et al. Familial occurrence of tardive dyskinesia. Acta Psychiatr Scand 2001; 104: 375-379.
12. Ismail B, Cantor-Graae E, McNeil TF. Neurodevelopmental origins of tardive like dyskinesia in schizophrenia patients and their siblings. Schizophr Bull 2001; 27: 629-641.
13. Egan MF, Apud J, Wyatt RJ. Treatment of tardive dyskinesia. Schizophr Bull 1997; 23: 583-609.
14. Sagara Y. Induction of reactive oxygen species in neurons by haloperidol. J Neurochem 1998; 71: 1002-1012.
15. Naidu PS, Singh A, Kulkarni SK. Carvedilol attenuates neurolepticinduced orofacial dyskinesia: possible antioxidant mechanisms. Br J Pharmacol 2002; 136: 193-200.
16. Delfs JM, Ellison GD, Mercugliano M, Chesselet MF. Expression of glutamic acid decarboxylase mRNA in striatum and pallidum in an animal model of tardive dyskinesia. Exp Neurol 1995; 133: 175-188.
17. Sakai K, Gao XM, Hashimoto T, Tamminga CA. Traditional and new antipsychotic drugs differentially alter neurotransmission markers in basal ganglia-thalamocortical neural pathways. Synapse 2001; 39: 152-160.
18. Fenton WS. Prevalence of spontaneous dyskinesia in schizophrenia. J Clin Psychiatry 2000; 61(Suppl 4): 10-14.
19. Pappa S, Dazzan P. Spontaneous movement disorders in antipsychoticnaive patients with first-episode psychoses: a systematic review. Psychol Med 2009; 39: 1065-1076.
20. Koning JP, Tenback DE, van Os J, Aleman A, Kahn RS, van Harten PN. Dyskinesia and parkinsonism in antipsychotic-naive patients with schizophrenia, first-degree relatives and healthy controls: a metaanalysis. Schizophr Bull 2010; 36: 723-731.
21. Lerer B, Segman RH, Fangerau H, Daly AK, Basile VS, Cavallaro R et al. Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism. Neuropsychopharmacology 2002; 27: 105-119.
22. Lerer B, Segman RH, Tan EC, Basile VS, Cavallaro R, Aschauer HN et al. Combined analysis of 635 patients confirms an age-related association of the serotonin receptor gene with tardive dyskinesia and specificity for the non-orofacial subtype. Int J Neuropsychopharmacol 2005; 8: 411-425.
23. Bakker PR, van Harten PN, van Os J. Antipsychotic-induced tardive dyskinesia and the Ser9Gly polymorphism in the DRD3 gene: a meta analysis. Schizophr Res 2006; 83: 185-192.
24. Bakker PR, van Harten PN, van Os J. Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions. Mol Psychiatry 2008; 13: 544-556.
25. Patsopoulos NA, Ntzani EE, Zintzaras E, Ioannidis JP. CYP2D6 polymorphisms and the risk of tardive dyskinesia in schizophrenia: a meta-analysis. Pharmacogenet Genomics 2005; 15: 151-158.
26. Tiwari AK, Deshpande SN, Lerer B, Nimgaonkar VL, Thelma BK. Genetic susceptibility to Tardive Dyskinesia in chronic schizophrenia subjects: V. Association of CYP1A2 1545 C4T polymorphism. Pharmacogenomics J 2007; 7: 305-311.
27. Tsai HT, Caroff SN, Miller DD, McEvoy J, Lieberman JA, North KE et al. A candidate gene study of tardive dyskinesia in the CATIE schizophrenia trial. Am J Med Genet B Neuropsychiatr Genet 2010; 153B: 336-340.
28. Aberg K, Adkins DE, Bukszár J, Webb BT, Caroff SN, Miller del D et al. Genomewide association study of movement-related adverse antipsychotic effects. Biol Psychiatry 2010; 67: 279-282.
29. Greenbaum L, Alkelai A, Rigbi A, Kohn Y, Lerer B. Evidence for association of the GLI2 gene with tardive dyskinesia in chronic schizophrenia patients. Mov Disord 2010; 25: 2809-2817.
30. Syu A, Ishiguro H, Inada T, Horiuchi Y, Tanaka S, Ishikawa M. Association of the HSPG2 gene with neuroleptic-induced tardive dyskinesia. Neuropsychopharmacology 2010; 35: 1155-1164.
31. Inada T, Koga M, Ishiguro H, Horiuchi Y, Syu A, Yoshio T et al. Pathwaybased association analysis of genome-wide screening data suggest that genes associated with the gamma-aminobutyric acid receptor signaling pathway are involved in neuroleptic-induced, treatmentresistant tardive dyskinesia. Pharmacogenet Genomics 2008; 18: 317-323.
32. Segman R, Neeman T, Heresco-Levy U, Finkel B, Karagichev L, Schlafman M et al. Genotypic association between the dopamine D3 receptor and tardive dyskinesia in chronic schizophrenia. Mol Psychiatry 1999; 4: 247-253.
33. Segman RH, Heresco-Levy U, Finkel B, Goltser T, Shalem R, Schlafman M et al. Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia. Mol Psychiatry 2001; 6: 225-229.
34. Guy W (1976). ECDEU Assessment Manual for Psychopharmacology, Revised edn. Department of Health, Education and Welfare: Washington DC.
35. Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry 1982; 39: 486-487.
36. Steen VM, Llie R, McEwan T, McCreadie RG. Dopamine D3 receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients. Mol Psychiatry 1997; 2: 139-145.
37. Andreassen OA, MacEwan T, Gulbrandsen AK, McCreadie RG, Steen VM. Non-functional CYP2D6 alleles and risk for neurolepticinduced movement disorders in schizophrenic patients. Psychopharmacology (Berl) 1997; 131: 174-179.
38. Løvlie R, Daly AK, Blennerhassett R, Ferrier N, Steen VM. Homozygosity for the Gly-9 variant of the dopamine D3 receptor and risk for tardive dyskinesia in schizophrenic patients. Int J Neuropsychopharmacol 2000; 3: 61-65.
39. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D et al. PLINK: a tool set for whole-genome association and populationbased linkage analyses. Am J Hum Genet 2007; 81: 559-575.
40. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209-1223.
41. Sullivan PF, Lin D, Tzeng JY, van den Oord E, Perkins D, Stroup TS et al. Genomewide association for schizophrenia in the CATIE study: results of stage 1. Mol Psychiatry 2008; 13: 570-584.
42. Stroup TS, McEvoy JP, Swartz MS, Byerly MJ, Glick ID, Canive JM et al. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull 2003; 29: 15-31.
43. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 2006; 38: 904-909.
44. Reich D, Price AL, Patterson N. Principal component analysis of genetic data. Nat Genet 2008; 40: 646-649.
45. Nasrallah HA. Focus on lower risk of tardive dyskinesia with atypical antipsychotics. Ann Clin Psychiatry 2006; 18: 57-62.
46. Pierre JM. Extrapyramidal symptoms with atypical antipsychotics: incidence, prevention and management. Drug Saf 2005; 28: 191-208.
47. Chong SA, Mahendran R, Machin D, Chua HC, Parker G, Kane J. Tardive dyskinesia among Chinese and Malay patients with schizophrenia. J Clin Psychopharmacol 2002; 22: 26-30.
48. Bhatia T, Sabeeha MR, Shriharsh V, Garg K, Segman RH, Uriel HL et al. Clinical and familial correlates of tardive dyskinesia in India and Israel. J Postgrad Med 2004; 50: 167-172.
49. Lin PI, Vance JM, Pericak-Vance MA, Martin ER. No gene is an island: the flip-flop phenomenon. Am J Hum Genet 2007; 80: 531-538.
50. Zaykin V, Shibata K. Genetic flip-flop without an accompanying change in linkage disequilibrium. Am J Hum Genet 2008; 82: 794-796.
51. Crowley JJ, Sullivan PF, McLeod HL. Pharmacogenomic genome-wide association studies: lessons learned thus far. Pharmacogenomics 2009; 10: 161-163.
52. Turner ST, Bailey KR, Fridley BL, Chapman AB, Schwartz GL, Chai HS et al. Genomic association analysis suggests chromosome 12 locus influencing antihypertensive response to thiazide diuretic. Hypertension 2008; 52: 359-365.
53. Sullivan PF. Spurious genetic associations. Biol Psychiatry 2007; 61: 1121-1126.
54. van den Oord EJ, Kuo PH, Hartmann AM, Webb BT, Möller HJ, Hettema JM et al. Genomewide association analysis followed by a replication study implicates a novel candidate gene for neuroticism. Arch Gen Psychiatry 2008; 65: 1062-1071.
55. Snow AD, Sekiguchi R, Nochlin D, Fraser P, Kimata K, Mizutani A et al. An important role of heparan sulfate proteoglycan (Perlecan) in a model system for the deposition and persistence of fibrillar A beta-amyloid in rat brain. Neuron 1994; 12: 219-234.
56. Rosenmann H, Meiner Z, Kahana E, Aladjem Z, Friedman G, Ben-Yehuda A et al. An association study of a polymorphism in the heparan sulfate proteoglycan gene (perlecan, HSPG2) and Alzheimer's disease. Am J Med Genet B Neuropsychiatr Genet 2004; 128B: 123-125.
57. Ruigrok YM, Rinkel GJ, Wijmenga C, Kasuya H, Tajima A, Takahashi T et al. Association analysis of genes involved in the maintenance of the integrity of the extracellular matrix with intracranial aneurysms in a Japanese cohort. Cerebrovasc Dis 2009; 28: 131-134.
58. Tammenmaa IA, McGrath JJ, Sailas E, Soares-Weiser K. Cholinergic medication for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 2002; 3: CD000207.
59. Rotundo RL, Rossi SG, Kimbell LM, Ruiz C, Marrero E. Targeting acetylcholinesterase to the neuromuscular synapse. Chem Biol Interact 2005; 157-158: 15-21.